INTERFACE BIOLOGICS, INC. (IBI) is a privately held early commercial stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices.
Total raised: $8M
Founded date: 2001
Investors 3
| Date | Name | Website |
| - | DSM | dsm.com |
| - | DSM Ventur... | venturing.... |
| - | BDC | bdc.ca/ |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 08.12.2011 | - | $1M | - |
| 10.01.2011 | Series B | $7M | - |
Mentions in press and media 2
| Date | Title | Description |
| 08.12.2011 | Interface Biologics Receives $1M in Financing | Interface Biologics, a Toronto, Ontario, Canada-based biomedical company, has received $1m in financing. The company, which received the financing as the result of a report by the Ontario Bioscience Industry Organization™ (OBIO™) that was p... |
| 10.01.2011 | Interface Biologics Completes $7M Series B Financing | Interface Biologics, Inc., a Toronto, Canada-based commercial stage developer of innovative biomedical-polymer products, completed a $7m Series B financing. The round was led by Business Development Bank of Canada, with participation from C... |